Eton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights

Dow Jones

Mar 03

By Elias Schisgall

Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns.

Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year.

The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products.

"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model," Eton Chief Executive Sean Brynjelsen said.

The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings.

Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 02, 2026 11:59 ET (16:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616935424"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616935424\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616935424?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 00:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616935424","market":"hk","top_or_hot":-1,"title":"Eton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns. \n</p>\n<p>\n  Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year. \n</p>\n<p>\n  The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products. \n</p>\n<p>\n  \"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said. \n</p>\n<p>\n  The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings. \n</p>\n<p>\n  Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 11:59 ET (16:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-03 00:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns. \n</p>\n<p>\n  Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year. \n</p>\n<p>\n  The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products. \n</p>\n<p>\n  \"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said. \n</p>\n<p>\n  The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings. \n</p>\n<p>\n  Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 11:59 ET (16:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ETON","symbol_name":"Eton Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616935424","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616935424","pubTimestamp":1772470740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns.Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year.The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products.\"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said.The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings.Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ETON":"Eton Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Eton Pharmaceuticals因收购Hemangeol美国商业化权而股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ETON":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns. \n\n\n  Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year. \n\n\n  The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products. \n\n\n  \"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said. \n\n\n  The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings. \n\n\n  Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 11:59 ET (16:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}